TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension

NCT07350070 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

HCC
Liver Cirrhosis
Portal Hypertension

Interventions

DRUG: TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol

Sponsor

Tongji Hospital